Research and Markets: Fenofibrate is Solvay Pharmaceuticals Flagship Product and Principal Growth Driver.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c48366) has announced the addition of the Espicom Business Intelligence Introduction Espicom Business Intelligence is a publisher of independent and impartial information and analysis services focusing on the pharmaceutical and medical device markets. Ltd, report: Solvay Prospects to 2010 to their offering. Operating in the three sectors of Pharmaceuticals, Chemicals and Plastics, Solvay is represented worldwide. Over 95 per cent of its sales come from outside Belgium and 49 per cent from outside the European Union. Current Growth Drivers Following the acquisition of Fournier Pharma, Solvay Pharmaceuticals flagship product and principal growth driver is now fenofibrate, a treatment for lipidic disorders which is sold as Tricor in the US and Lipanthyl elsewhere. Other growth drivers include: the male hormone product, Androgel, which has been Solvays top-selling product for a number of years; the neuroscience products, Marinol (dronabinol) and Serc (betahistine); the influenza vaccine, Influvac; the pancreatic enzyme, Creon; and Teveten (eprosartan mesylate) for hypertension. Key Late-Stage Products Dualtis/Synordia (fenofibrate+metformin metformin /met·for·min/ (met-for´min) an antihyperglycemic agent that potentiates the action of insulin, used in the treatment of type 2 diabetes mellitus. met·for·min n. ) was filed in the EU in July 2006 for dyslipidaemia and if approved, it would be the first product on the market that combines a lipid-lowering drug with an oral antidiabetic in one tablet. The atypical antipsychotic, bifeprunox, for the treatment of schizophrenia The concept of a cure as such in the treatment of schizophrenia remains controversial, as there is no consensus on the definition of "treatment" in the case of schizophrenia, although some criteria for the remission of symptoms have recently been suggested. is expected to be filed in the EU during 2008, rather than 2006 as originally planned. Solvay and Wyeth submitted an NDA (Non Disclosure Agreement) An agreement signed between two parties that have to disclose confidential information to each other in order to do business. In general, the NDA states why the information is being divulged and stipulates that it cannot be used for any for schizophrenia to the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. in October 2006. SLV SLV abbr. standard launch vehicle 308, an oral therapy being developed for the treatment of the less-advanced stages of Parkinson's disease, is in Phase III trials. Zolip (fenofibrate+statin) is in Phase III trials for dyslipidaemia, with launch scheduled for 2010. Products Mentioned Include: Dualtis/Synordia (fenofibrate+metformin) SLV308 Zolip (fenofibrate+statin) Summary Pharmaceutical Company Intelligence Reports provide a full review of the companys activities, from its origins to its latest corporate activity, including mergers and acquisitions, agreements, divestitures, major purchasing contracts and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. . Sections are included on products, international activities and R&D, as well as a full, in-depth five year financial analysis. An introduction to each report and a full table of contents is provided for review. More than 40 Company Intelligence Reports are currently available. Companies Mentioned * 4SC * AEterna Zentaris Inc * Berna Biotech AG * Biovail Corporation * Bristol-Myers Squibb * Elan Corporation plc * Eli Lilly * Innogenetics NV * Lundbeck * Novozymes A/S * Pepscan Systems BV/ServiceXS BV * Petrovax Pharm * QuatRx Pharmaceuticals Company * Quintiles Quintiles Transnational Corp. is a contract research organization which serves the pharmaceutical, biotechnology and healthcare industries. History Quintiles was founded in 1982 by Dennis Gillings and as of 2007 it has 18,000 employees. Transnational Corporation * Schering-Plough * SLA (1) (StereoLithography Apparatus) See 3D printing. (2) (Service Level Agreement) A contract between the provider and the user that specifies the level of service expected during its term. Pharma AG * Wyeth For more information visit http://www.researchandmarkets.com/reports/c48366. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion